Achtung: hohPublica wurde am 18.11.2024 aktualisiert. Falls Sie auf Darstellungsfehler stoßen, löschen Sie bitte Ihren Browser-Cache (Strg + Umschalt + Entf). *** Attention: hohPublica was last updated on November 18, 2024. If you encounter display errors, please delete your browser cache (Ctrl + Shift + Del).
 

Serological protection rates against TBEV infection in blood donors from a highly endemic region in Southern Germany

dc.contributor.authorDobler, Gerhard
dc.contributor.authorEuringer, Kathrin
dc.contributor.authorKaier, Klaus
dc.contributor.authorBorde, Johannes P.
dc.date.accessioned2024-09-03T13:37:59Z
dc.date.available2024-09-03T13:37:59Z
dc.date.issued2023de
dc.description.abstractBackground: Tick-borne encephalitis (TBE) is the most significant tick-borne disease in Europe and Asia, with more than 10,000 cases per year worldwide. A surge of reported TBE cases can be observed despite the availability of highly efficient vaccines. There is little known about the serological immune protection rate of the population in Germany. The seroprotection rate is defined as the presence of neutralizing antibodies. In contrast, the vaccination rate, as defined by public health agencies, may differ from the true protection rate in a population. Materials and Methods: 2220 blood samples from inhabitants of the county Ortenaukreis in the Federal State of Baden-Württemberg in Germany were included in the study. These were tested for anti-TBEV IgG antibodies by an anti-TBEV-IgG-ELISA. Subsequently, all TBEV-IgG positive samples were confirmed for neutralizing antibodies in the micro serum neutralization assay. Results: From the overall 2220 samples, 2104 were included in the comparison because of the selection of specific age groups (ages 20–69). In our sample size, we found an average serological protection rate (presence of neutralizing antibodies) of 57% (518/908) for the female blood donors and of 52% (632/1196) for the male blood donors. Discussion: In this study, we present new findings on a highly endemic region in southern Germany. Additionally, we present current data regarding the serological TBEV protection rates in the Ortenaukreis in southern Germany and compare these with a dataset published by the RKI, which is based on vaccination reports of the primary care providers and health care insurers, and with a self-reporting study conducted by a vaccine manufacturer. Our results significantly exceed the official numbers of average active vaccination status by 23.2% for females and by 21% for males. This might indicate an even longer persistence of TBE-vaccination-induced antibody titers than previously assumed.en
dc.identifier.urihttps://hohpublica.uni-hohenheim.de/handle/123456789/16485
dc.identifier.urihttps://doi.org/10.3390/vaccines11030522
dc.language.isoengde
dc.rights.licensecc_byde
dc.source2076-393Xde
dc.sourceVaccines; Vol. 11, No. 3 (2023) 522de
dc.subjectTBEV
dc.subjectTBE
dc.subjectGermany
dc.subjectEpidemiology
dc.subjectVaccine
dc.subjectProtection
dc.subjectNS1
dc.subject.ddc610
dc.titleSerological protection rates against TBEV infection in blood donors from a highly endemic region in Southern Germanyen
dc.type.diniArticle
dcterms.bibliographicCitationVaccines, 11 (2023), 3, 522. https://doi.org/10.3390/vaccines11030522. ISSN: 2076-393X
dcterms.bibliographicCitation.issue3
dcterms.bibliographicCitation.journaltitleVaccines
dcterms.bibliographicCitation.volume11
local.export.bibtex@article{Dobler2023, url = {https://hohpublica.uni-hohenheim.de/handle/123456789/16485}, doi = {10.3390/vaccines11030522}, author = {Dobler, Gerhard and Euringer, Kathrin and Kaier, Klaus et al.}, title = {Serological protection rates against TBEV infection in blood donors from a highly endemic region in Southern Germany}, journal = {Vaccines}, year = {2023}, volume = {11}, number = {3}, }
local.export.bibtexAuthorDobler, Gerhard and Euringer, Kathrin and Kaier, Klaus et al.
local.export.bibtexKeyDobler2023
local.export.bibtexType@article

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
vaccines-11-00522.pdf
Size:
1002.83 KB
Format:
Adobe Portable Document Format
No Thumbnail Available
Name:
vaccines-11-00522-s001.zip
Size:
174.08 KB
Format:
Unknown data format